Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

43.64USD
28 Apr 2017
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$43.65
Open
$43.71
Day's High
$43.75
Day's Low
$43.50
Volume
2,725,084
Avg. Vol
2,430,136
52-wk High
$45.84
52-wk Low
$36.76

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $75,686.30
Shares Outstanding(Mil.): 1,728.00
Dividend: 0.26
Yield (%): 2.42

Financials

  ABT.N Industry Sector
P/E (TTM): 48.62 29.41 30.38
EPS (TTM): 0.90 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

MEDIA-India govt rejects Abbott, Medtronic applications to withdraw stents - PTI in Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

27 Apr 2017

CORRECTED-OFFICIAL-China's richest man deepens sports foray with global marathons deal

BEIJING, April 26 China's Dalian Wanda Group, controlled by the country's richest man Wang Jianlin, has signed a deal to sponsor races with the world's top organizer, Abbott World Marathon Majors (WMM), the latest move by Wanda to expand its global sports business.

26 Apr 2017

BRIEF-Abbott Laboratories develops 2 new science-based nutrition drinks for patients undergoing surgery

* Abbott Laboratories - developed two new science-based nutrition drinks for patients undergoing surgery Source text for Eikon: Further company coverage:

26 Apr 2017

China's richest man deepens sports foray with global marathons deal

BEIJING China's Dalian Wanda Group, controlled by the country's richest man Wang Jianlin, has signed a deal to sponsor races with the world's top organizer, Abbott World Marathon Majors (WMM), the latest move by Wanda to expand its global sports business.

26 Apr 2017

MEDIA-Abbott, Medtronic, Boston Scientific to recall new generation stents from India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

24 Apr 2017

Abbott sees Alere as challenging 'fixer-upper' after revised deal

Abbott Laboratories said it was looking to close the recently revised deal to buy Alere Inc in the coming months, calling the diagnostics company "a bit of a fixer-upper".

19 Apr 2017

UPDATE 3-Abbott sees Alere as challenging "fixer-upper" after revised deal

* Closing of new Alere deal is a little unpredictable - CFO (Adds conference call details; Updates shares)

19 Apr 2017

BRIEF-Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call

* Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call

19 Apr 2017

Abbott posts 29.7 pct rise in quarterly sales

April 19 Diversified healthcare company Abbott Laboratories reported a 29.7 percent rise in quarterly sales on Wednesday, driven by its $25 billion acquisition of St. Jude Medical.

19 Apr 2017

BRIEF-Abbott Q1 adjusted earnings per share $0.48 from continuing operations

* Q1 adjusted earnings per share $0.48 from continuing operations

19 Apr 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.47 -0.27
Pfizer Inc. (PFE.N) $33.92 +0.06
Novartis AG (NOVN.S) CHF76.55 -0.35
Merck & Co., Inc. (MRK.N) $62.33 -0.25
Sanofi SA (SASY.PA) €86.61 +0.64
AstraZeneca plc (AZN.L) 4,637.50 -60.50
GlaxoSmithKline plc (GSK.L) 1,550.00 -8.50
Eli Lilly and Co (LLY.N) $82.06 +0.73
Amgen, Inc. (AMGN.OQ) $163.32 +0.60
Boston Scientific Corporation (BSX.N) $26.38 +0.20

Earnings vs. Estimates